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Abstract
Introduction: The association between thrombotic 
thrombocytopenic purpura (TTP) and systemic lupus 
erythematosus (SLE) is uncommon. Diagnosis is 
often difficult because of their clinical and biological 
similarities. The presence of TTP in SLE worsens the 
prognosis and causes high mortality in the absence of 
early therapeutic interventions. 
Case report: We report the case of a 20 year-old man, 
admitted with nephrotic range proteinuria, hematuria 
and rapidly progressive renal failure. He also had 
anemia, thrombocytopenia and pericardial effusion. 
The diagnosis of SLE was made based on these clinical 
findings along with positive antinuclear and anti 
dsDNA antibodies. Renal biopsy revealed class IV/ V 
lupus nephritis (LN) with active lesions of thrombotic 
microangiopathy. The evolution of neurological deficit, 
persistent thrombocytopenia and active microangiopathic 
changes suggested the diagnosis of associated TTP. The 
patient was treated initially with corticosteroids and 
cyclophosphamide.  Plasmapheresis could only be started 
16 days later. Mycophenolate mofetil and rituximab were 
successively tried in the absence of improvement in renal 
function and persistent thrombocytopenia. The patient’s 
neurological condition deteriorated necessitating transfer 
to the intensive care unit and mechanical ventilation. 
There he developed pneumonia and died of septic shock 
two months after presentation. 
Conclusion: The coexistence of TTP and SLE needs to 
be considered early in SLE patients with complicated 
course. It may not respond to the conventional 
immunosuppressive treatment of SLE.
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Introduction
The association of thrombotic thrombocytopenic 
purpura (TTP) and systemic lupus erythematosus (SLE) 
is extremely rare with an incidence estimated at 0.5 % 
[1]. The presence of TTP in SLE worsens the prognosis 
and increases mortality, necessitating early therapeutic 
intervention. 
In TTP, a constitutional or acquired deficiency of the 
activity of protease (ADAMTS-13) of von Willebrand 
factor is noted. ADAMTS-13 is a zinc metalloprotease 
which cleaves a high molecular weight complex called 
“ultra-wide complex of von Willebrand factor” in the 
circulating blood. ADAMTS-13 has a well demonstrated 
antithrombotic effect and its deficiency leads to 
accumulation of multimeric  forms of high molecular 
weight von Willebrand factor. This promotes platelet 
adhesion and aggregation leading to the formation of 
vascular microthrombosis. ADAMTS-13 deficiency 
has been demonstrated in more than 80% of patients 
with acquired forms of TTP [2]. The remaining 
cases correspond to a deficit-free TTP for which the 
pathophysiology remains unclear. The high prevalence 
of anti-ADAMTS-13 antibodies in autoimmune diseases 
such as SLE is known to lead to reduced ADAMTS-13 
activity [3]. Moreover, the activation of the classical 
complement pathway has been implicated in the induction 
of thrombotic microangiopathy in lupus nephritis as 
evidenced by glomerular C4d deposits [4]. The diagnosis 
of TTP in SLE patients is difficult because of their 
clinical and biological similarities; hemolytic anemia, 
thrombocytopenia, neurological deficit, fever and renal 
dysfunction. The presence of schistocytes or fragmented 
granulocytes (GR) is an element in favor of TTP [5, 6]. 
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Discussion 
In this case, the presence of microangiopathic hemolytic 
anemia, impaired neurological status and persistent 
thrombocytopenia suggested the diagnosis of TTP 
associated with SLE. The association TTP and SLE is 
extremely rare and serious [1, 7]. The activation of the 
classical complement pathway has been implicated 
recently in induction of thrombotic microangiopathy in 
lupus nephritis as evidenced by glomerular deposits of 
C4d [4]. In this case complement level was normal but 
C4d stain was not available.
The prognosis of TTP has significantly improved by 
plasma exchange (PE) compared to treatment with 
fresh frozen plasma (FFP) alone, with the survival rate 
increasing from 10% to 75-92% [1]. The therapeutic 
benefit of PE is achieved through a transfusion effect 
and a subtractive effect. Transfused plasma provides 
the deficient factor ADAMTS-13 while plasmapheresis 
removes the mega multimers of von Willebrand factor and 
any circulating autoantibodies. The British Committee for 
Standards in Hematology recommends that PE therapy 
continues for a minimum of two days after the return of 
platelet counts to normal, normalization of neurological 
status, increased hemoglobin and normalization of 
LDH [1]. The residual presence of schistocytes in the 
peripheral blood after normalization of platelet count is 
common and is not predictive of relapse [8]. Rituximab 
(RTX) is a humanized monoclonal antibody directed 
against B lymphocytes. Some reports suggest that RTX is 
a promising therapy in severe lupus nephritis refractory 
to other immunosuppressive therapies [9]. RTX is also 
recommended in the treatment of relapsing or refractory 
forms of TTP [10]. 
In our case, although plasma exchange was considered 
early in the course of the disease, it became available 
only 16 days later. This delay could have contributed 
to the neurological deterioration and worsening 
thrombocytopenia. Immunosuppressive therapy consisting 
initially of cyclophosphamide and corticosteroids, and 
later MMF and RTX, was used for the treatment of 
proliferative lupus nephritis. It was well tolerated, but 
didn’t improve the patient’s condition. TTP with multi-
organ failure is associated with a high mortality of about 
35%. In this context, neurological impairment is a poor 
prognostic feature [11].
Conclusion
TTP diagnosis is difficult in the context of SLE because 
of similarity between the two pathologies. This diagnosis 
must be considered early because early diagnosis 
and prompt treatment may have a positive impact on 
prognosis. 
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Case presentation
Here we report the case of a 20 year-old man with 
no significant past medical or surgical history who 
presented complaining of generalized body swelling of 
one month duration. He also complained of non-pruritic 
rash affecting the trunk and upper limbs. On physical 
examination, he was conscious, fully alert and oriented. 
He had facial swelling and bilateral lower limb edema. 
He was not febrile and his blood pressure was 130/80 
mmHg. Neurological examination was not remarkable 
apart from brisk tendon reflexes. He had a maculo-
papular rash affecting the trunk and upper limbs. The rest 
of the physical examination was unremarkable.
The laboratory workup revealed active urinary sediment 
with protein 2+ and blood 3+.  His urinary protein 
excretion was 5.5 g/day, serum protein 5.7 g/dl, serum 
albumin 2.3 g/dl, serum creatinine 3.5 mg/dl and 
creatinine clearance 40 ml/minute. A complete blood 
count revealed normochromic normocytic anemia with 
hemoglobin of 8.2 g/dl and reticulocyte count of 44200/
µl, thrombocytopenia with platelet count of 75 000/µl 
and leukopenia with WBC of  2800/µl. Schistocytes were 
positive at 3% and direct Coomb’s test was negative. Bone 
marrow examination was normal. The LDH was two 
and a half times the normal value. Viral serologies were 
negative and complement levels were normal. He had a 
positive antinuclear antibody (ANA) with a titer of 1:640 
IU/ml.  Anti double stranded DNA (dsDNA) antibody 
level was elevated at 251U/ml and antiphospholipids 
antibody (APL) level was 21 IU/ml. Chest X-ray was 
normal. Renal ultrasound showed increased size of 
both kidneys. The renal Doppler study was normal. 
Echocardiography showed pericardial effusion with a 
thickness of 14 mm.
The diagnosis of SLE was made based on renal, 
hematological and cardiac involvement together with 
positive ANA and anti- ds-DNA antibodies. The SLE 
disease activity index (SLEDAI) score on admission 
mounted to 15. The patient received three pulsed doses 
of methylprednisolone followed by oral prednisolone, 
after which pancytopenia was corrected. Renal biopsy 
was taken and it revealed class IV / V lupus nephritis 
with active lesions of thrombotic microangiopathy 
(TMA) (Figures 1-2). Cyclophosphamide was started at 
a dose of 0.75g/m2 along with supportive hemodialysis. 
The patient received fresh frozen plasma infusions but 
plasmapheresis was only available after 16 days of 
admission. At day-20, evolution was marked  by severe 
neurological deterioration with right temporal hypo-dense 
lesions on CT brain and recurrence of thrombocytopenia. 
At this stage, the presence of microangiopathic hemolytic 
anemia, impaired neurological status and persistent 
thrombocytopenia suggested the diagnosis of TTP 
associated with SLE. After one month of treatment the 
patient remained anuric and continued to have severe 
thrombocytopenia with platelet counts < 50000/mm3. 
Cyclophosphamide was substituted with mycophenolate 
mofetil (MMF). At day 45, salvage therapy with 
rituximab (500 mg first dose) was tried in the absence 
of improvement in renal function and persistent 
thrombocytopenia. Three days later, the patient developed 
convulsions, supraventricular tachycardia and respiratory 
distress that required his transfer to the intensive care unit 
(ICU) and mechanical ventilation. During his stay in the 
ICU, he developed pneumonia and died of septic shock 
19 days after ICU admission.
Figure 1: Glomerulus with endocapillary proliferation (EP) 
and intracapillary thrombi (T). Light microscopy (x 400 
trichrome stain) 
Figure 2: Glomerulus with extracapillary proliferation 
(XP). Light microscopy (x 250 trichromestain) 
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In this case, the presence of microangiopathic hemolytic 
anemia, impaired neurological status and persistent 
thrombocytopenia suggested the diagnosis of TTP 
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classical complement pathway has been implicated 
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increasing from 10% to 75-92% [1]. The therapeutic 
benefit of PE is achieved through a transfusion effect 
and a subtractive effect. Transfused plasma provides 
the deficient factor ADAMTS-13 while plasmapheresis 
removes the mega multimers of von Willebrand factor and 
any circulating autoantibodies. The British Committee for 
Standards in Hematology recommends that PE therapy 
continues for a minimum of two days after the return of 
platelet counts to normal, normalization of neurological 
status, increased hemoglobin and normalization of 
LDH [1]. The residual presence of schistocytes in the 
peripheral blood after normalization of platelet count is 
common and is not predictive of relapse [8]. Rituximab 
(RTX) is a humanized monoclonal antibody directed 
against B lymphocytes. Some reports suggest that RTX is 
a promising therapy in severe lupus nephritis refractory 
to other immunosuppressive therapies [9]. RTX is also 
recommended in the treatment of relapsing or refractory 
forms of TTP [10]. 
In our case, although plasma exchange was considered 
early in the course of the disease, it became available 
only 16 days later. This delay could have contributed 
to the neurological deterioration and worsening 
thrombocytopenia. Immunosuppressive therapy consisting 
initially of cyclophosphamide and corticosteroids, and 
later MMF and RTX, was used for the treatment of 
proliferative lupus nephritis. It was well tolerated, but 
didn’t improve the patient’s condition. TTP with multi-
organ failure is associated with a high mortality of about 
35%. In this context, neurological impairment is a poor 
prognostic feature [11].
Conclusion
TTP diagnosis is difficult in the context of SLE because 
of similarity between the two pathologies. This diagnosis 
must be considered early because early diagnosis 
and prompt treatment may have a positive impact on 
prognosis. 
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